✦ LIBER ✦

41 POSTER Clinical and biomarker responses in a phase I study of BAY 57 9352 – a VEGFR-2 inhibitor – administered as continuous dosing in patients with advanced solid tumors

✍ Scribed by D. Strumberg; O. Christensen; R. Strecker; M.E. Scheulen; A. Frost; P. Rajagopalan; D. Voliotis; M. Zuehlsdorf; G. Wensing; K. Mross

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

72 POSTER Phase I, safety, pharmacokinet

✍ H. Gelderblom; J. Verweij; N. Steeghs; E. de Koning; A. van Erkel; L. van Doorn; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

381 A phase I study of BAY 43-90006, a n

✍ A. Awada; A. Hendlisz; T. Gil; B. Schwartz; S. Bartholomeus; E. Brendel; D. de V 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 147 KB

A clinical phase I and biomarker study o

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 281 KB

Phase I, dose escalation and pharmacokin

✍ Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Y 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 436 KB

343 POSTER Phase I dose escalation study

✍ H.A. Burris; G. Hudes; S. Jones; J. Cheng; D. Spigel; M. Mariani; H. Macdonald; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

38 POSTER Phase I and pharmacological st

✍ F.A.L.M. Eskens; M.J.A. de Jonge; L. van Doorn; T. Isoe; K. Hayashi; S. Hussain; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB